Emerging antiviral targets for influenza A virus

Trends in Pharmacological Sciences

Volumn 30, Issue 6, 2009, Pages 269-277

  Krug, Robert M ^a   Aramini, James M ^b  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b RUTGERS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAMANTANE; AMANTADINE; ANTIVIRUS AGENT; HEMAGGLUTININ; NONSTRUCTURAL PROTEIN 1; NUCLEOPROTEIN; OSELTAMIVIR; PROTEIN M2; RIMANTADINE; RNA DIRECTED RNA POLYMERASE; SIALIDASE; TERT BUTYLHYDROQUINONE; VIRUS PROTEIN; ZANAMIVIR;

ARTICLE; DRUG DESIGN; DRUG RESEARCH; DRUG STRUCTURE; DRUG TARGETING; INFLUENZA VIRUS A; INFLUENZA VIRUS A H5N1; NONHUMAN; PANDEMIC; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; VIRUS RESISTANCE;

ANIMALS; ANTIVIRAL AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA, HUMAN; RNA REPLICASE; VIRAL NONSTRUCTURAL PROTEINS; ZANAMIVIR;

EID: 68649122631     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2009.03.002     Document Type: Article

References (74)

1. Lamb R.A., and Krug R.M. Orthomyxoviridae: the viruses and their replication. In: Knipe D.M., and Howley P.M. (Eds). Fields Virology. 4th edition (2001), Lippincott Williams & Wilkins 1487-1532
2. Wright P.F., and Webster R.G. Orthomyxoviruses. In: Knipe D.M., and Howley P.M. (Eds). Fields Virology. 4th edition (2001), Lippincott Williams & Wilkins 1533-1579
3. Reid A.H., et al. The 1918 Spanish influenza: integrating history and biology. Microbes Infect. 3 (2001) 81-87
4. Horimoto T., and Kawaoka Y. Influenza: lessons from past pandemics, warnings from current incidents. Nat. Rev. Microbiol. 3 (2005) 591-600
5. Noah D.L., and Krug R.M. Influenza virus virulence and its molecular determinants. In: Maramorsch K., and Shatkin A.J. (Eds). Advances in Virus Research Vol. 65 (2005), Elsevier 121-145
6. de Jong J.C., et al. A pandemic warning?. Nature 389 (1997) 554
7. Subbarao K., et al. Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness. Science 279 (1998) 393-396
8. Peiris J.S., et al. Re-emergence of fatal human influenza A subtype H5N1 disease. Lancet 363 (2004) 617-619
9. Taubenberger J.K., et al. Characterization of the 1918 influenza virus polymerase genes. Nature 437 (2005) 889-893
10. Hayden F.G. Antivirals for influenza: historical perspectives and lessons learned. Antiviral Res. 71 (2006) 372-378
11. Longini Jr. I.M., et al. Containing pandemic influenza at the source. Science 309 (2005) 1083-1087
12. Ferguson N.M., et al. Strategies for mitigating an influenza pandemic. Nature 442 (2006) 448-452
13. Germann T.C., et al. Mitigation strategies for pandemic influenza in the United States. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 5935-5940
14. Hay A.J., et al. The molecular basis of the specific anti-influenza action of amantadine. EMBO J. 4 (1985) 3021-3024
15. Lamb R.A., et al. The influenza A virus M2 ion channel protein and its role in the influenza virus life cycle. In: Wimmer D. (Ed). Receptor-Mediated Virus Entry Into Cells (1994), Cold Spring Harbor Press 303-321
16. von Itzstein M., et al. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 363 (1993) 418-423
17. Kim C.U., et al. Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis and structural analysis of carbocyclic sialiac acid analogues with potent anti-influenza activity. J. Am. Chem. Soc. 119 (1997) 681-690
18. Mendel D.B., et al. Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS 4071 protects mice and ferrets against influenza infection. Antimicrob. Agents Chemother. 42 (1998) 640-646
19. Hay A.J., et al. Molecular basis of resistance of influenza A viruses to amantadine. J. Antimicrob. Chemother. 18 Suppl. B (1986) 19-29
20. Suzuki H., et al. Emergence of amantadine-resistant influenza A viruses: epidemiological study. J. Infect. Chemother. 9 (2003) 195-200
21. Deyde V.M., et al. Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide. J. Infect. Dis. 196 (2007) 249-257
22. Puthavathana P., et al. Molecular characterization of the complete genome of human influenza H5N1 virus isolates from Thailand. J. Gen. Virol. 86 (2005) 423-433
23. de Jong M.D., et al. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N. Engl. J. Med. 353 (2005) 2667-2672
24. Le Q.M., et al. Avian flu: isolation of drug-resistant H5N1 virus. Nature 437 (2005) 1108
25. Yen H.L., et al. Neuraminidase inhibitor-resistant recombinant A/Vietnam/1203/04 (H5N1) influenza viruses retain their replication efficiency and pathogenicity in vitro and in vivo. J. Virol. 81 (2007) 12418-12426
26. Lackenby A., et al. Emergence of resistance to oseltamivir among influenza A(H1N1) viruses in Europe. Euro Surveill. 13 (2008) 8026
27. Stouffer A.L., et al. Structural basis for the function and inhibition of an influenza virus proton channel. Nature 451 (2008) 596-599
28. Schnell J.R., and Chou J.J. Structure and mechanism of the M2 proton channel of influenza A virus. Nature 451 (2008) 591-595
29. Cady S.D., et al. Structure of amantadine-bound M2 transmembrane peptide of influenza A in lipid bilayers from magic-angle-spinning solid-state NMR: the role of Ser31 in amantadine binding. J. Mol. Biol. 385 (2009) 1127-1141
30. Jing X., et al. Functional studies indicate amantadine binds to the pore of the influenza A virus M2 proton-selective ion channel. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 10967-10972
31. Varghese J.N., et al. Structure of the influenza virus glycoprotein antigen neuraminidase at 2.9 Å resolution. Nature 303 (1983) 35-40
32. Gubareva L.V., et al. Inhibition of replication of avian influenza viruses by the neuraminidase inhibitor 4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid. Virology 212 (1995) 323-330
33. Russell R.J., et al. The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. Nature 443 (2006) 45-49
34. Wilson I.A., et al. Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 A resolution. Nature 289 (1981) 366-373
35. Bullough P.A., et al. Structure of influenza haemagglutinin at the pH of membrane fusion. Nature 371 (1994) 37-43
36. Bodian D.L., et al. Inhibition of the fusion-inducing conformational change of influenza hemagglutinin by benzoquinones and hydroquinones. Biochemistry 32 (1993) 2967-2978
37. Hoffman L.R., et al. Structure-based identification of an inducer of the low-pH conformational change in the influenza virus hemagglutinin: irreversible inhibition of infectivity. J. Virol. 71 (1997) 8808-8820
38. Yu K.L., et al. Structure-activity relationships for a series of thiobenzamide influenza fusion inhibitors derived from 1,3,3-trimethyl-5-hydroxy-cyclohexylmethylamine. Bioorg. Med. Chem. Lett. 12 (2002) 3379-3382
39. Russell R.J., et al. Structure of influenza hemagglutinin in complex with an inhibitor of membrane fusion. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 17736-17741
40. Krug R.M., et al. Intracellular warfare between human influenza viruses and human cells: the roles of the viral NS1 protein. Virology 309 (2003) 181-189
41. Hale B.G., et al. The multifunctional NS1 protein of influenza A viruses. J. Gen. Virol. 89 (2008) 2359-2376
42. Hatada E., and Fukuda R. Binding of influenza A virus NS1 protein to dsRNA in vitro. J. Gen. Virol. 73 (1992) 3325-3329
43. Lu Y., et al. Binding of the influenza virus NS1 protein to double-stranded RNA inhibits the activation of the protein kinase that phosphorylates the elF-2 translation initiation factor. Virology 214 (1995) 222-228
44. Wang W., et al. RNA-binding by the novel helical domain of the influenza virus NS1 protein requires its dimer structure and a small number of specific basic amino acids. RNA 5 (1999) 195-205
45. Chien C.Y., et al. Biophysical characterization of the complex between double-stranded RNA and the N-terminal domain of the NS1 protein from influenza A virus: evidence for a novel RNA-binding mode. Biochemistry 43 (2004) 1950-1962
46. Min J.-Y., and Krug R.M. The primary function of RNA binding by the influenza A virus NS1 protein in infected cells: inhibiting the 2′-5′ OAS/RNase L pathway. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 7100-7105
47. Nemeroff M.E., et al. Influenza virus NS1 protein interacts with the cellular 30 kDa subunit of CPSF and inhibits 3′end formation of cellular pre-mRNAs. Mol. Cell 1 (1998) 991-1000
48. Kim M.J., et al. Human influenza viruses activate an interferon-independent transcription of cellular antiviral genes: outcome with influenza A virus is unique. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 10096-10101
49. Noah D.L., et al. Cellular antiviral responses against influenza A virus are countered at the posttranscriptional level by the viral NS1A protein via its binding to a cellular protein required for the 3′ end processing of cellular pre-mRNAs. Virology 307 (2003) 386-395
50. Hale B.G., et al. Influenza A virus NS1 protein binds p85beta and activates phosphatidylinositol-3-kinase signaling. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 14194-14199
51. Min J.-Y., et al. A site on the influenza A virus NS1 protein mediates both inhibition of PKR activation and temporal regulation of viral RNA synthesis. Virology 363 (2007) 236-243
52. Shin Y.K., et al. Influenza A virus NS1 protein activates the phosphatidylinositol 3-kinase (PI3K)/Akt pathway by direct interaction with the p85 subunit of PI3K. J. Gen. Virol. 88 (2007) 13-18
53. Chien C.Y., et al. A novel RNA-binding motif in influenza A virus non-structural protein 1. Nat. Struct. Biol. 4 (1997) 891-895
54. Liu J., et al. Crystal structure of the unique RNA-binding domain of the influenza virus NS1 protein. Nat. Struct. Biol. 4 (1997) 896-899
55. Yin C., et al. Conserved surface features form the double-stranded RNA-binding site of non-structural protein 1 (NS1) from influenza A and B viruses. J. Biol. Chem. 282 (2007) 20584-20592
56. Cheng A., et al. Structural basis for dsRNA recognition by NS1 protein of influenza A virus. Cell Res. 19 (2008) 187-195
57. Twu K.Y., et al. The CPSF30 binding site on the NS1A protein of influenza A virus is a potential antiviral target. J. Virol. 80 (2006) 3957-3965
58. Bornholdt Z.A., and Prasad B.V. X-ray structure of influenza virus NS1 effector domain. Nat. Struct. Mol. Biol. 13 (2006) 559-560
59. Hale B.G., et al. Structure of an avian influenza A virus NS1 protein effector domain. Virology 378 (2008) 1-5
60. Xia S., et al. Structure of NS1A effector domain from the influenza A/Udorn/72 virus. Acta Crystallogr. D Biol. Crystallogr. 65 (2009) 11-17
61. Das K., et al. Structural basis for suppression by influenza A virus of a host antiviral response. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 13093-13098
62. Basu D., et al. Novel influenza virus NS1 antagonists block replication and restore innate immune function. J. Virol. 83 (2009) 1881-1891
63. Portela A., and Digard P. The influenza virus nucleoprotein: a multifunctional RNA-binding protein pivotal to virus replication. J. Gen. Virol. 83 (2002) 723-734
64. Krug R.M., et al. Expression and replication of the influenza virus genome. In: Krug R.M. (Ed). The influenza viruses (1989), Plenum Press 89-152
65. Newcomb L.L., et al. Interaction of the influenza a virus nucleocapsid protein with the viral RNA polymerase potentiates unprimed viral RNA replication. J. Virol. 83 (2009) 29-36
66. Ye Q., et al. The mechanism by which influenza A virus nucleoprotein forms oligomers and binds RNA. Nature 444 (2006) 1078-1082
67. Ng A.K., et al. Structure of the influenza virus A H5N1 nucleoprotein: implications for RNA binding, oligomerization, and vaccine design. FASEB J. 22 (2008) 3638-3647
68. Obayashi E., et al. The structural basis for an essential subunit interaction in influenza virus RNA polymerase. Nature 454 (2008) 1127-1131
69. He X., et al. Crystal structure of the polymerase PA(C)-PB1(N) complex from an avian influenza H5N1 virus. Nature 454 (2008) 1123-1126
70. Ghanem A., et al. Peptide-mediated interference with influenza A virus polymerase. J. Virol. 81 (2007) 7801-7804
71. Guilligay D., et al. The structural basis for cap binding by influenza virus polymerase subunit PB2. Nat. Struct. Mol. Biol. 15 (2008) 500-506
72. Dias A., et al. The cap-snatching endonuclease of influenza virus polymerase resides in the PA subunit. Nature 458 (2009) 914-918
73. Yuan P., et al. Crystal structure of an avian influenza polymerase PA(N) reveals an endonuclease active site. Nature 458 (2009) 909-913
74. Ilyushina N.A., et al. Combination therapy, a potential strategy for reducing the emergence of drug-resistant influenza a variants. Antiviral Res. 70 (2006) 121-131